What is William Blair’s Estimate for NMRA FY2029 Earnings?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Analysts at William Blair issued their FY2029 earnings estimates for Neumora Therapeutics in a research report issued to clients and investors on Thursday, January 2nd. William Blair analyst M. Minter expects that the company will earn $1.47 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

Other research analysts have also issued reports about the stock. Royal Bank of Canada lowered shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $29.00 to $4.00 in a research report on Thursday. JPMorgan Chase & Co. downgraded Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Neumora Therapeutics in a research note on Friday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $18.40.

Neumora Therapeutics Trading Up 10.2 %

Shares of NASDAQ:NMRA opened at $2.17 on Monday. Neumora Therapeutics has a 1-year low of $1.83 and a 1-year high of $21.00. The stock has a market cap of $350.59 million, a PE ratio of -1.16 and a beta of 3.34. The stock’s fifty day simple moving average is $10.47 and its two-hundred day simple moving average is $11.51.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter last year, the business posted ($1.14) earnings per share.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Robert A. Lenz sold 5,563 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now owns 322,966 shares of the company’s stock, valued at $4,847,719.66. The trade was a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the transaction, the director now directly owns 20,100 shares of the company’s stock, valued at approximately $342,303. This trade represents a 41.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Several hedge funds have recently made changes to their positions in NMRA. JPMorgan Chase & Co. boosted its stake in Neumora Therapeutics by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock worth $851,000 after purchasing an additional 1,629 shares during the period. Barclays PLC lifted its holdings in shares of Neumora Therapeutics by 352.9% in the third quarter. Barclays PLC now owns 129,210 shares of the company’s stock worth $1,708,000 after buying an additional 100,678 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after acquiring an additional 694,385 shares during the period. Wexford Capital LP grew its stake in Neumora Therapeutics by 90.1% during the third quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock valued at $2,878,000 after acquiring an additional 103,285 shares in the last quarter. Finally, State Street Corp grew its stake in Neumora Therapeutics by 65.3% during the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after acquiring an additional 707,409 shares in the last quarter. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.